Gut-Brain Axis Holds Promise for Treating Anxiety Disorders, Depression, and Schizophrenia

Strategic Insights -

Research at Helwan University has shed light on the gut-brain axis and its potential role in treating anxiety disorders, depression, and schizophrenia. A scoping review of 145 studies found consistent patterns of microbial dysbiosis, short-chain fatty acid disturbances, kynurenine pathway alterations, and immune activation across disorders. The study suggests that the gut-brain axis provides a promising mechanistic framework and therapeutic target for major psychiatric disorders, but future progress will depend on harmonized biomarker platforms, rigorous controlled trials, and integration of multi-omics approaches to establish clinical utility.

Key Takeaways:

  • The gut-brain axis represents a multidirectional communication system linking the gastrointestinal microbiota with neural, immune, and metabolic pathways.
  • Research has identified consistent patterns of microbial dysbiosis, short-chain fatty acid disturbances, kynurenine pathway alterations, and immune activation across anxiety disorders, depression, and schizophrenia.
  • Biomarker studies have identified candidate microbial taxa and metabolites with potential diagnostic or prognostic relevance, though reproducibility was limited.
  • Interventional approaches, including probiotics, prebiotics, synbiotics, diet-based strategies, and fecal microbiota transplantation, have shown modest benefits for depressive and anxiety symptoms but yielded mixed or preliminary findings in schizophrenia.
  • The study suggests that the gut-brain axis provides a promising mechanistic framework and therapeutic target for major psychiatric disorders, but further research is needed to establish clinical utility.
  • The review included 145 studies that were conducted between 2015 and 2025 and covered mechanisms, biomarkers, and therapeutic implications of the gut-brain axis in depression, anxiety, and schizophrenia.

Statistics:

  • 145 studies were included in the review.
  • The studies were conducted between 2015 and 2025.
  • The research identified 145 eligible studies among 8,625 searches in five databases (MEDLINE, Embase, PsycINFO, Web of Science, and Scopus).
  • 145 studies were included in the review, with 145 studies yielding candidate microbial taxa and metabolites with potential diagnostic or prognostic relevance.

Sources:

  • The research was published in Middle East Current Psychiatry (2025, 32(1):1-21).
  • The publisher for Middle East Current Psychiatry is SpringerOpen.
  • The free version of the article is available at https://doi-org.sdpl.idm.oclc.org/10.1186/s43045-025-00585-z.
  • The research was conducted at Helwan University by Kirolos Eskandar and colleagues.